How Can You Tell There Are Russian Troops in Syria? Just Look for Some Soldier Selfies
Although Russian President Vladimir Putin has denied that he is sending troops to Syria, selfies taken by Russian soldiers and posted on social media are telling a different story.
Russian investigative journalist Ruslan Leviev reports that an increasing number of experienced Russian troops have been deployed to a naval maintenance facility in Tartus, along Syria’s Mediterranean coast. His source? Status updates and photos posted on Russia’s two biggest social networking sites by members of the 810th marine brigade, an infantry force in the Russian navy.
Related: As Putin Targets Dissent, U.S. Democracy Group Banned in Russia
One photo Leviev found is of a career soldier named Mazhnikov, who appears to be at the naval facility in Syria. Another soldier, Anatoly Golota, also a member of the 810th brigade, updated his status on the Russian version of Facebook with the words, “Off to Syria :)).”
Russia has not denied that it’s been supplying weapons to the Syrian government and helping train the Syrian military. But Putin knows that combat troops are a different story.
The naval maintenance facility at Tartus is small, and in the past has been manned by just a handful of personnel. Leviev reports that the number of troops stationed at the facility is growing, and the troops are experienced contract soldiers, not draftees.
Videos uploaded to social media sites have raised concerns that Russian troops might be involved in combat inside Syria, according to an article in Foreign Policy. However, beyond the footage, which shows a Russian-made BTR-82A armored vehicle firing its gun in Syria, no other substantial evidence of active combat involving Russian troops has been found.
While the marines may or may not be directly involved in the fighting, the presence of Russian troops in Syria shows how hard Putin is pressing for a victory by the Assad regime. Now if he can just teach his soldiers how to avoid giving themselves away on social media.
Top Reads From The Fiscal Times
- Putin’s Economy May Be in Even Worse Shape Than It Looks
- China Sends a Message with Its New ‘Carrier Killer Missile
- In Showing Off Physical Strength, Putin Tries to Hide Political Weaknesses
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.